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GENERAL COMMENTS
Thank you for letting me review the manuscript "Korean OBEsity Surgical treatment Study (KOBESS): protocol of a prospective multicenter cohort study on obese patients undergoing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass".
The authors present an ambitious and well-planned study on bariatric surgery (RYGB and SG) , and a possibility to compare these results with a weight loss drug from a concomitant RCT. In addition, quality of life is studied by validated questionnaires. The present study seems ongoing, inclusion in 2016-2017, why probably very few changes can be made to the methodology. The manuscript is well-written and clear.
Minor comments concerning the study protocol Objectives: Complete; although a 1y follow up after bariatric surgery is very short, especially in studying cost-effectiveness. Please see additional benefits below. Study methods: The preoperative screening program and planned examinations during the postoperative follow up is well-planned and seems complete. Inclusion criteria meets modern international standards. 1. How many centres take part in this multicentre study? Is there a minimal number of procedures for a participating surgeon? 2. In the sample size calculation, a concomitant RCT with a weight loss drug is used. How will the patients be allocated to this RCT or to the surgical arm? 3. The standardization of operative procedures is most important, especially in a multicentre study. This potential problem seems to be well addressed, however, how will the mesenteric defects be closed in RYGB (staples or running suture; absorbable/non-absorbable)? 4. The measurement of body composition by bioimpedance has been questioned, but I feel confident with the repeated fatmeasuring CT. 5. The use of an oral glucose test is commendable; however, some RYGB-patients may experience severe dumping postoperatively. 6. Of the two economic analyses, the Markov model concerning long-term costs is of cause more interesting than the 1y cost-utility analysis. Moreover, the comparison between bariatric surgery and the locaserin-treated group might be biased by differences in baseline characteristics of the included patients. Ethics: Approved by Institutional Review Boards at the participating hospitals. 7. It is most important that all bariatric patients have a life-long follow up. In the protocol, the funder will provide free perioperative tests (preop to 1y?), but who is responsible for the continued follow up to avoid micronutrient deficiencies in the long run?
Minor comments concerning the manuscript Abstract: Please, omit the word "sustained" concerning weight loss on line 46, as this cannot be determined in the present 1y-study. Small typo on page 14, line 4, should be "Psychosocial" problem scale.
An additional benefit lies is the multicentre registration of adverse events, i.e. perioperative complications and other problems during the first year, and the standardization of the operative technique, in this case even including video-based reviews of performed procedures. This will be an important contribution to the national development of bariatric surgery in Korea.
As a scientist and bariatric surgeon, I would like to encourage the nationwide KOBESS study group to perform a clinical long-term follow up of all included patients, for example at 5 and/or 10 years postoperatively.
VERSION 1 -AUTHOR RESPONSE
Reply to Reviewer #1:
We completely agree with your concern that endoscopic screening is problematic after RYGB. Therefore, we decided not to design the trial as a randomized one and let the patient choose which surgical procedure they want performed after being fully informed. We have added a double-balloon endoscopy option for the evaluation of the remnant stomach in patients who undergo RYGB (page 10, lines, 17-19 lines). The small sample size is the main limitation of this trial, as we mentioned in the paper. In order to minimize the bias caused by this, we decided to allocate 50 patients to each surgical group. Furthermore, stratification according to the preoperative BMI will be performed to distribute patients evenly to each group. We have added this information to the section "Sample size justification and data analysis plan" (page 8, lines, 17-19). A brief description of the statistical analysis has also been added (pages, 8-9). We would like to thank you for your kind and instructive comments on our article.
Comments of Reviewer #2:
1. How many centres take part in this multicentre study? Is there a minimal number of procedures for a participating surgeon? 2. In the sample size calculation, a concomitant RCT with a weight loss drug is used. How will the patients be allocated to this RCT or to the surgical arm? 3. The standardization of operative procedures is most important, especially in a multicentre study. This potential problem seems to be well addressed, however, how will the mesenteric defects be closed in RYGB (staples or running suture; absorbable/non-absorbable)? 4. The measurement of body composition by bioimpedance has been questioned, but I feel confident with the repeated fat-measuring CT. 5. The use of an oral glucose test is commendable; however, some RYGB-patients may experience severe dumping postoperatively. 6. Of the two economic analyses, the Markov model concerning long-term costs is of cause more interesting than the 1y cost-utility analysis. Moreover, the comparison between bariatric surgery and the locaserin-treated group might be biased by differences in baseline characteristics of the included patients. 7. It is most important that all bariatric patients have a life-long follow up. In the protocol, the funder will provide free perioperative tests (preop to 1y?), but who is responsible for the continued follow up to avoid micronutrient deficiencies in the long run? Minor comments concerning the manuscript Abstract: Please, omit the word "sustained" concerning weight loss on line 46, as this cannot be determined in the present 1y-study. Small typo on page 14, line 4, should be "Psychosocial" problem scale.
Reply to Reviewer #2:
We completely agree that these comments. Comment #1.
Ten surgeons from 7 hospitals, each of whom performed more than 50 cases of bariatric surgery, will participate in this trial. However, no limit will be set on the experience of the operator because it is one of the goals of this trial to standardize and improve the surgical technique of all participating surgeons. We have added the information about the participating hospitals to page 7, line 24). Comment #2. Participants can decide which clinical trials (RCT for weight control drug or KOBESS) they want to enroll in. We added this sentence to the section "Sample size justification and data analysis plan" (page 8, lines 6-7). Comment #3. All mesenteric defects are closed with a running suture made of non-absorbable materials. We have added this information to the section "Surgical interventions and postoperative follow-up" (page 11, lines 8-9). Comment #4. We totally agree with this comment. However, we are concerned about the risk of radiation from repeated CT scans. Therefore, we decided to restrict the number of CT scans to two and perform repeated BIA to evaluate fat distribution changes. We added this information to the section "Assessment of outcomes" (page 12, lines 6-8). Comment #5. We think this is a very important point. We have added the following sentence "If the patient refuses the OGTT because of uncomfortable symptoms such as dumping syndrome when taking glucose, the OGTT can be omitted." (pages, 12-13). We have changed the protocol accordingly.
